We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Adlai Nortye Ltd. Sponsored ADR (ANL) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Adlai Nortye Ltd. Sponsored ADR (ANL - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
Adlai Nortye Ltd. Sponsored ADR is one of 916 individual stocks in the Medical sector. Collectively, these companies sit at #8 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Adlai Nortye Ltd. Sponsored ADR is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for ANL's full-year earnings has moved 39.5% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the most recent data, ANL has returned 727.8% so far this year. Meanwhile, the Medical sector has returned an average of -0.1% on a year-to-date basis. This shows that Adlai Nortye Ltd. Sponsored ADR is outperforming its peers so far this year.
Another Medical stock, which has outperformed the sector so far this year, is Thermo Fisher Scientific (TMO - Free Report) . The stock has returned 14.4% year-to-date.
For Thermo Fisher Scientific, the consensus EPS estimate for the current year has increased 1.1% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Adlai Nortye Ltd. Sponsored ADR belongs to the Medical - Biomedical and Genetics industry, a group that includes 449 individual companies and currently sits at #152 in the Zacks Industry Rank. Stocks in this group have lost about 0.3% so far this year, so ANL is performing better this group in terms of year-to-date returns.
In contrast, Thermo Fisher Scientific falls under the Medical - Instruments industry. Currently, this industry has 78 stocks and is ranked #94. Since the beginning of the year, the industry has moved -5.5%.
Investors interested in the Medical sector may want to keep a close eye on Adlai Nortye Ltd. Sponsored ADR and Thermo Fisher Scientific as they attempt to continue their solid performance.
View the Zacks #1 Rank List
Image: Bigstock
Is Adlai Nortye Ltd. Sponsored ADR (ANL) Stock Outpacing Its Medical Peers This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Adlai Nortye Ltd. Sponsored ADR (ANL - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
Adlai Nortye Ltd. Sponsored ADR is one of 916 individual stocks in the Medical sector. Collectively, these companies sit at #8 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Adlai Nortye Ltd. Sponsored ADR is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for ANL's full-year earnings has moved 39.5% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the most recent data, ANL has returned 727.8% so far this year. Meanwhile, the Medical sector has returned an average of -0.1% on a year-to-date basis. This shows that Adlai Nortye Ltd. Sponsored ADR is outperforming its peers so far this year.
Another Medical stock, which has outperformed the sector so far this year, is Thermo Fisher Scientific (TMO - Free Report) . The stock has returned 14.4% year-to-date.
For Thermo Fisher Scientific, the consensus EPS estimate for the current year has increased 1.1% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Adlai Nortye Ltd. Sponsored ADR belongs to the Medical - Biomedical and Genetics industry, a group that includes 449 individual companies and currently sits at #152 in the Zacks Industry Rank. Stocks in this group have lost about 0.3% so far this year, so ANL is performing better this group in terms of year-to-date returns.
In contrast, Thermo Fisher Scientific falls under the Medical - Instruments industry. Currently, this industry has 78 stocks and is ranked #94. Since the beginning of the year, the industry has moved -5.5%.
Investors interested in the Medical sector may want to keep a close eye on Adlai Nortye Ltd. Sponsored ADR and Thermo Fisher Scientific as they attempt to continue their solid performance.